Program
notiretatug rezetecan
Also written as “SHR-A2102”, “SHR-A2102 for Injection” and “SHR-A2102 ; Adebrelimab injection”.
In Jiangsu HengRui Medicine’s pipeline, Nectin-4 ADC
. Its studies are mostly in Urinary Bladder Neoplasms · Carcinoma, Transitional Cell · Squamous Cell Carcinoma of Head and Neck · Uterine Cervical Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 1414 open or running | phase 3since Dec 12, 2024 | Jan 18, 2023 | Dec 2026phase 2 · NCT06915142 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-A2102
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 18, 2023First studies: 2 phase 1 studiesFirst studyNCT05701709, NCT05735275
- Apr 26, 2024Phase 2 study in Advanced Solid TumorsNCT06417554 · 80 planned · China
- Jun 6, 2024Phase 2 study in Esophageal NeoplasmsNCT06474468 · 148 planned · China
- Oct 10, 20242 phase 2 studiesNCT06639347, NCT06654440
- Dec 12, 2024Phase 3 study in Advanced Urothelial CarcinomaNCT06738251 · 402 planned · China
- Mar 11, 2025Phase 3 study in Muscular Invasive Bladder Cancer (MIBC)NCT06879145 · 740 planned · China
- Mar 20, 2025Phase 2 study in Advanced Solid TumorsNCT06895928 · 400 planned · China
- Apr 1, 2025Phase 2 study in Advanced Malignant TumourNCT06915142 · 300 planned · China
- Jul 1, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07059221 · 210 planned · China
- Sep 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07175220 · 200 planned · China
- Jan 30, 2026Phase 3 study in Carcinoma, Transitional CellNCT07393542 · 453 planned · China
- Feb 11, 2026Phase 3 study in Uterine Cervical NeoplasmsNCT07418749 · 398 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourNCT06915142
- Mar 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07059221
- May 31, 2027Primary completion: phase 2 study in Advanced Urothelial CarcinomaNCT06639347
- Dec 2027Primary completion: phase 3 study in Uterine Cervical NeoplasmsNCT07418749
TargetBeta
“Nectin-4 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of notiretatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) nectin-4 (PVRL4) conjugated, via a cleavable linker, to rezetecan, a derivative of the topoisomerase-1 inhibitor exatecan, with potential a…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of notiretatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) nectin-4 (PVRL4) ”NCIt, by rule
Other programs on NECTIN4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enfortumab vedotinrule | Astellas Pharma | phase 4 | 20 |
| bulumtatug fuvedotinrule | Mabwell (Shanghai) Bioscience | phase 3 | 13 |
| Sutantatug Envedotinrule | CSPC Pharmaceutical Group | phase 3 | 6 |
| zelenectide pevedotinrule | bicycletx-limited | phase 2 | 5 |
| Anti-nectin-4 Antibody-drug Conjugate MK-3120rule | Merck | phase 2 | 5 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-nectin-4 Antibody-drug Conjugate IPH4502rule | innate-pharma | phase 1 | 1 |
| Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rule | rondo-therapeutics | phase 1 | 1 |
| CT-202rule | context-therapeutics-inc | phase 1 | 1 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07418749Uterine Cervical Neoplasms · China | 3 | Recruiting | Dec 2027 | 398 |
| NCT07393542Carcinoma, Transitional Cell · China | 3 | Recruiting | Jan 31, 2028 | 453 |
| NCT07175220Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Oct 2028 | 200 |
| NCT07059221Squamous Cell Carcinoma of Head and Neck · China | 2 | Recruiting | Mar 2027 | 210 |
| NCT06915142Advanced Malignant Tumour · China | 2 | Recruiting | Dec 2026 | 300 |
| NCT06895928Advanced Solid Tumors · China | 2 | Recruiting | Dec 2028 | 400 |
| NCT06879145Muscular Invasive Bladder Cancer (MIBC) · China | 3 | Recruiting | Dec 2031 | 740 |
| NCT06738251Advanced Urothelial Carcinoma · China | 3 | Recruiting | Jul 2026 | 402 |
| NCT06654440Advanced Gynecological Malignancy · China | 2 | Recruiting | Aug 31, 2025 | 100 |
| NCT06639347Advanced Urothelial Carcinoma · China | 2 | Recruiting | May 31, 2027 | 90 |
| NCT06474468Esophageal Neoplasms · China | 2 | Recruiting | Oct 2026 | 148 |
| NCT06417554Advanced Solid Tumors · China | 2 | Recruiting | Dec 31, 2031 | 80 |
| NCT05735275Advanced Or Metastatic Solid Tumor Malignancies · China | 1 | Recruiting | Aug 31, 2025 | 252 |
| NCT05701709Advanced Solid Tumors · China | 1 | Recruiting | Aug 31, 2025 | 395 |
How it is read
Names in the registry
- “SHR-A2102”, 7 entries
- “SHR-A2102 for Injection”, 2 entries
- “SHR-A2102 ; Adebrelimab injection”, 1 entry
- “SHR-A2102 + Disitamab Vedotin For Injection”, 1 entry
- “SHR-A2102 and Adebrelimab”, 1 entry
Conditions, from the studies’ own filings
- Urinary Bladder Neoplasms, 1 study
- Carcinoma, Transitional Cell, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Uterine Cervical Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.